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Human HOX genes encode transcription factors that act as master regulators of embryonic development. They are important in several processes such as cellular morphogenesis 
and differentiation. The HOXB5 gene in particular has been reported in some types of 
neoplasm, but not in oral cancer. Objective: The present study investigated the expression 
of HOXB5 in oral squamous cell carcinoma (SCC) and in non-tumoral adjacent tissues, 
focusing on verifying its possible role as a broad tumor-associated gene and its association 
with histopathological and clinical (TNM) characteristics. Material and Methods: RT-PCR was 
performed to amplify HOXB5 mRNA in 15 OSCCs and adjacent non-tumoral epithelium. 
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mRNA expression and TNM or histological grade. Conclusion: HOXB5 is expressed in OSCCs 
and its role in cancer progression should be further investigated.
Key words: Genes, homeobox. Carcinoma, squamous cell. Gene expression. RT-PCR, 
neoplasm staging.
INTRODUCTION
Squamous cell carcinoma (SCC) accounts 
to more than 90% of malignant tumors of the 
oral cavity and oropharynx. It is often related to 
considerable mortality and morbidity rates, and 
presents a variable etiology related to alcohol and 
tobacco abuse associated with genetic factors5,13. 
Despite considerable advances in the diagnostic and 
therapeutic possibilities, the prognosis of epithelial 
tumors in the oral cavity is still very poor15. In view 
of this, the literature raises the interest in studies 
that focus on the search of biological markers that 
can lead to an accurate prognosis followed by the 
appropriate management5,13,15. Since alterations of 
gene expression in normal tissues can be responsible 
for malignant phenotypes, the investigation of 
deregulated genes in cancerous tissues may provide 
important information regarding new markers for 
cancers14.
Recently, the literature has suggested that several 
molecular processes that underlie carcinogenesis 
might be involved with embryogenesis11. In this 
context, the homeobox genes, master regulators 
of morphogenesis and cell differentiation during 
embryogenesis, have emerged as potential candidates 
to be also involved with carcinogenesis1,9,16. This 
important family of genes codes regulatory proteins 
that act as transcriptional factors controlling the 
development of several tissues including orofacial 
tissue1,16.
The HOX family plays a key role in the 
morphogenesis of vertebrate embryo cells, providing 
regional information along the main body axis and 
are vital to many aspects related to cellular growth 
and differentiation1,23. The human genome contains 
39 HOX genes, which are clustered in a similar 
arrangement of 13 paralog groups in four different 
chromosomal regions denominated HOX A, B, C, 
and D20,25,26.
HOX genes have been described deregulated 
in several cancers including leukemia, colon, skin, 
prostate, breast, ovary cancers, and more recently 
in oral cavity7,24-26. These studies suggest that the 
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disturbance in the normal pattern of HOX gene 
expression links up with carcinogenesis in a variety 
of organs. Preliminary data from the Cancer Genome 
Project (Ludwig Institute, São Paulo, SP, Brazil) 
showed an overexpression of HOXB5 in head and 
neck tumors (data not published). However, until 
now, few HOX genes have been correlated with 
normal oral mucosa and oral SCC (OSCC)10.
Overall, the participation of HOX genes in oral 
cancer and the factors that control their expression 
in normal tissues and cancer remain unknown and 
should be further elucidated. The present study 
investigated the expression of HOXB5 in OSCC and 
in non-tumoral adjacent tissues, focusing on verifying 
its possible role as a broad tumor-associated gene 
and its association with histopathological and clinical 
(TNM) characteristics.
MATERIAL AND METHODS
Sample collection
Tissues (n=15) were obtained from OSCC cases 
and adjacent non-tumoral mucosa at the Head 
and Neck Surgery Department, Clinics Hospital, 
São Paulo, Brazil, following the ethical procedures. 
The investigations were performed after approval 
by a local institutional review board (IRB) and in 
accordance with the Helsinki Declaration. Samples 
from adjacent non-tumoral mucosa presenting no 
histological evidence of dysplasia (data not shown) 
were used as control. Tumors were separated by nodal 
involvement (N+) or not (N0) after histopathological 
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were recorded (Figure 1) and each sample was 
prepared for histopathological analysis according to 
standard methods (H&E staining). Histopathological 
information was examined based on clinical data 
and pathological criteria (low or high grade). 
Samples were frozen in liquid nitrogen and stored 
at -80°C until the RNA extraction by the TRizol 
method (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. To rule out the 
possibility of contamination with genomic DNA, the 
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grade (Invitrogen) at room temperature for 15 min, 
followed by 10 min at 65ºC with the addition of 25 mM 
of EDTA. The RNA integrity of samples was evaluated 
based on the intensity of 28 S and 18 S rRNA bands 
on agarose gels.
cDNA preparation
Reverse transcription-PCR (RT-PCR) was 
performed in 20 mL of reaction mixture containing 
2 mL of oligo (dT) and 4 mg of total RNA at 70°C 
for 10 min. After that, 2 mL of DTT, 1 mL of dNTPs 
and 4 mL of 5x buffer were incubated during 10 min 
at 25°C, followed by 1 mL of Superscript II reverse 
transcriptase (Invitrogen) for 50 min at 42°C, and a 
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Semi-quantitative real-time polymerase 
chain reaction (RT-PCR)
Specific HOXB5 primer sets were designed 
using GeneTool 1.0 software (BioTools Inc., 
Alberta, Canada). About 5 mL of the reverse-
transcribed mixture (cDNA) was used as a 
template for PCR, using Taq polymerase Platinum 
(Invitrogen) in the presence of 200 mM HOXB5 
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5’-GCCTCGTCTATTTCGGTGA-3’). Amplification 
was carried out in a PT100 thermocycler (MJ 
Research, Watertown, MA, USA) for 35 cycles (40 
s of denaturation at 94°C, 1 min of annealing 
at 65°C and 1 min of extension at 72°C). 
Alternatively, conventional RT-PCR reactions for 
b-actin gene (5’-CCTTCCTGGGCATGGAGTCCTG-3’ 
and 5’-GGAGCAATGATCTTGATCTTC3’) were carried 
out for all samples and used as an endogenous 
control of positive amplification demonstrating 
the presence of mRNA in all tested samples. A 
negative control (absence of cDNA) was included in 
all RT-PCR reactions to ensure the absence of DNA 
contamination and false positives. The amplicons 
were analyzed by electrophoresis on 2% NuSieve 
agarose gels (FMC Bioproducts, Rockland, Manie 
USA), and documented using digital photographs. 
Semi-quantitative analyses were performed based on 
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products and using the NIH IMAGE 1.55 program. For 
each sample, the intensity of bands obtained with the 
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b-actin RT-PCR products.
Statistical analysis
After normalization using β-actin gene, the 
triplicate of each data point generated by semi-
quantitative assays was submitted to statistical 
analysis. The difference of the expression levels of 
HOXB5 in OSCC specimens and non-tumoral tissues, 
as well as the association among HOXB5 mRNA 
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were analysed by chi-square test and Fisher’s test 
(p<0.01).
RESULTS
Clinical features, pathological data and HOXB5 
expression in OSCC and non-tumoral tissues are 
summarized in Figure 1. In detail, the majority of 
the studied patients were male (10/15) representing 
66.7%, while 5 patients were female (33.3%). The 
mean age was 58 years raging from 22 to 87 years. 
The preferential site of the OSCC was the tongue (10 
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26.7%) and maxilla (1 case, 6.6%). According to 
HOXB5 expression in oral squamous cell carcinoma
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as T4 (60.1%). Nine cases presented lymph node 
involvement and none had metastases (M0).
Presence and viability of cDNA was checked in all 
samples using an endogenous control gene (b-actin). 



	W&	
&
		
\
~	W!"#$%
expression was observed in both OSCC and in non-
tumoral (NT) tissues, its expression was more present 
in OSCC. HOXB5 transcripts were found in 9/15 
(60%) of NT, and in 14/15 (93.3%) of OSCC tissues 
(Figure 3). As shown in Figure 1, in patients 2, 4, 
6, 8, 11 and 13, HOXB5 expression was observed 
exclusively in OSCC tissues and no expression was 
observed in NT tissues, while only in the patient 3 
the opposite was observed.
Additionally, patients 1, 5, 7, 9, 10, 12, 14 and 15 
presented positive expression of HOXB5 in both sites 
(tumoral and NT samples). When grouping patients 
according to the N status, in the absence of nodal 
involvement (N0), 2/6 (33.3%) patients showed 
HOXB5 expression in both sites (+/+), 3/6 (50%) 
patients showed HOXB5 expression only in tumor 
Patient 
ID
Site Gender Race Age TNM Histologic
graduation
HOXB5 in
normal tissue
HOXB5 in 
tumor
1 Tongue F W 56 T1N0M0 High grade + +
2 Tongue F W 78 T1N0M0 Low grade - +
3 Floor M W 50 T4N0M0 High grade + -
4 Tongue F W 25 T4N0M0 High grade - +
5 Maxilla M B 87 T4N0M0 Low grade + +
6 Floor M W 56 T4N0M0 Low grade - +
7 Tongue F W 70 T1N2M0 Low grade + +
8 Tongue M W 80 T1N2M0 Low grade - +
9 Tongue M W 56 T2N1M0 High grade + +
10 Tongue F W 55 T2N2M0 Low grade + +
11 Tongue M W 22 T4N1M0 Low grade - +
12 Floor M W 50 T4N2M0 Low grade + +
13 Tongue M W 58 T4N2M0 Low grade - +
14 Tongue M W 67 T4N2M0 Low grade + +
15 Floor M W 60 T4N3M0 High grade + +
Figure 1- Clinical and histological parameters of the OSCC analyzed and the respective HOXB5 mRNA expression in 
OSCC and corresponding normal tissues
M=Male; F=female; W=white; B=black
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sample (patient); C-=Negative control (no template); STD=molecular weight standard; N=non-tumoral mucosa; T=tumor
Figure 3- HOXB5 mRNA expression in OSCC cases and normal tissues. Numbers represent the sample (patient); 
C-=Negative control (no template); STD=molecular weight standard; N=non-tumoral mucosa; T=tumor
TUCCI R, CAMPOS MS, MATIZONKAS-ANTONIO LF, DURAZZO M, PINTO DS Jr, NUNES FD
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(-/+), while 1/6 patient presented HOXB5 expression 
exclusively in normal site (+/-). On the other hand, 
when nodal involvement (N+) was present, 5/9 
(55.5%) patients showed HOXB5 expression in 
both sites (+/+), 3/9 (33.3%) presented HOXB5 
expression exclusively in tumoral sites (-/+), and 
no patient showed HOXB5 expression only in normal 
site (+/-).
After histopathological analysis, 10 cases were 
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between HOXB5 expression and clinical features 
(TNM) and histological grade of the patients studied 
(P=1.00, chi-square test).
DISCUSSION
The expression of HOXB5 was analyzed in OSCC 
samples and compared to NT adjacent tissues in 
order to obtain information about its involvement in 
oral carcinogenesis. Also, this study tried to verify a 
possible association of the HOXB5 expression with 
TNM, clinical data and histological grade. According 
to the results, HOXB5 was expressed in most 
(93.3%) of the OSCC analyzed, independently of the 
TNM status. However, when considering N status, 
a regulation based on losses and gains of HOXB5 
expression in normal sites versus tumoral sites could 
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Previous studies showed changes in the expression 
of some HOX genes in several tumours including 
oesophagus, leukemia, stomach and colon, but until 
now, this point was poorly addressed in OSCC26. 
Recently, a study described the presence of HOX 
genes in oral dysplasias, OSCC and normal mucosa 
suggesting that misexpressions of particular HOX 
genes are implicated in the development of oral 
dysplasia and OSCC10. Moreover, another recent 
study using human minor salivary gland showed 
that HOXB13 transcripts were differently expressed 
in normal mucous and serous acini, concluding that 
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genes in salivary gland carcinogenesis6.
Currently, is common to assume an important 
re lat ionship between carc inogenes is  and 
embryogenesis1,9, suggesting that genes involved 
with development, as HOX genes, are deregulated 
during malignant transformation and cancer 
establishment7,16,19. Moreover, homeobox genes are 
reported as useful tools to identify undifferentiated 
tumors or metastasis with unknown origin19.
Among the HOX genes, HOXB5 was found 
overexpressed in head and neck SSC (Ludwig Institute, 
São Paulo, Brazil, data not shown). Furthermore, 
HOXB5 is located at 17p21.3 chromosome, a region 
recently reported with high percentage of loss of 
heterozygosis in head and neck SCC2 which suggests 
that this gene should be better investigated in OSCC. 
Using RT-PCR, HOXB5 transcripts were frequently 
amplified in tumoral and non-tumoral samples. 
Although HOXB5 expression was more present in 
OSCC samples (93.3%) than in non-tumoral tissues 
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(P=0.03, chi-square test), and could be considered 
as a “borderline significance”. A larger number 
of standardized samples, in a future quantitative 
investigation, would help clarifying this issue.
Regarding the parameters included in this study, 
the cervical lymph node metastasis was used since 
it is a poor prognostic indicator in patients with 
OSCCs12. The results showed that, when grouping 
patients according to the presence or not of nodal 
involvement, 50% of the patients with N0 showed gain 
of HOXB5 in tumor site represented by the relation 
-/+ (non tumoral-tissue/tumor). Interestingly, 55% 
of the patients with nodal involvement (N+) showed 
expression in both sites, but none of the patients 
presented HOXB5 expression only in non-tumoral 
tissues. Taken together, these data suggest a trend 
that a loss of HOXB5 expression in normal sites and 
a gain of HOXB5 in tumor sites can be related to 
nodal involvement and poor prognosis. However, 
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tumor that metastasizes to the regional nodes can be 
considered aggressive and, because of this biologic 
characteristic, could cause a propensity to recur 
after treatment. If the latter concept is correct, a 
relationship between neck nodes and recurrence at 
the primary site would seem logical. Therefore, it 
would be interesting to verify if HOXB5 expression in 
epithelium adjacent to OSCC is related to recurrence 
or incidence of second primary tumors. Unfortunately, 
all patients studied here were treated in less than 1 
year. It would also be interesting to see the epithelial 
expression of HOXB5 in different areas of the mouth, 
and related to the diverse patterns of keratinization, 
but this was not the goal of this study. Also, the 
inclusion of normal oral tissue would be ethically 
questionable.
It is widely accepted that the processes of normal 
embryogenesis and neoplasia share many pathways, 
and that tumor development is an aberrant form of 
organogenesis1,21. Typically, those homeobox genes 
that are upregulated or “gained” expression in 
carcinoma normally show expression patterns that 
are restricted to undifferentiated or proliferative cells. 
Conversely, homeobox genes that are downregulated 
or “lost” in carcinoma are normally expressed in fully 
differentiated tissues. These considerations can justify 
the variable pattern of HOXB5 expression found in 
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non-tumoral and tumoral samples. This issue was 
HOXB5 expression in oral squamous cell carcinoma
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not considered a technical artifact since mRNA was 
of optimal quality, and experiments were extensively 
optimized and performed in triplicate. Since it is well 
known that homeobox are regulated by co-factors8,18, 
it is possible that in those cases where HOXB5 was not 
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clinical features (TNM) and histological grade of 
the patients studied. Perhaps a larger number of 
patients would help establishing a correlation. The 
absence of standardization of the patients might 
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the data generated by RT-PCR assay to TNM or 
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many authors report a strict correlation between 
these parameters and the prognosis of OSCC3,17. On 
the other hand, while some authors consider the TNM 
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the prognosis of SCC22, others consider it limited4. In 
the same way, histological grading usually does not 
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CONCLUSION
The results presented here support that expression 
of HOX genes is associated with OSCC. Since over 
90% of OSCC samples presented HOXB5 expression 
versus 60% of NT tissues, it can be suggested 
that HOXB5 may be related to the malignant 
phenotypes. In this case, a future quantitative 
analysis may be suitable to verify if the HOXB5 gene 
is overexpressed in OSCC tissues, thus making our 
suggestion stronger. Presence of HOXB5 only in 
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homeobox genes are probably regulated by losses 
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was observed among the HOXB5 expression, clinical 
features (TNM) and histological grade of the patients 
studied. Since several parameters were analyzed 
in the present study, future investigations should 
include a larger number of standardized samples.
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